Last edition
News about "Syndax "
Syndax Gets FDA Approval of Revuforj for Relapsed or Refractory Acute Leukemia
The safety evaluation of Revuforj was based on an FDA analysis of 135 patients with R/R acute leukemia with a KMT2A translocation who were treated with Revuforj.
Syndax | 16/11/2024 | By Aishwarya | 307
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members